142 completed, 57 terminated, 49 recruiting, 24 active not recruiting. 305 Phase 2, 40 Phase 1, 20 Phase 3.
Follow Emory University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1 / Phase 2 | Not yet recruiting | Emory University | 12 | 2027-01-01 | 2026-05-08 |
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response Ketamine - Epilepsy, Depressive Symptoms | Phase 2 | Not yet recruiting | Emory University | 37 | 2026-12-01 | 2026-08-17 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| PFAS Clinical Trial Cholestyramine, Centrum - Environmental Exposure | Phase 2 | Not yet recruiting | Emory University | 300 | 2026-11-01 | 2026-09-23 |
| Baricitinib Curative Repression of HIV-1 Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV | Phase 2 | Not yet recruiting | Emory University | 35 | 2026-10-01 | 2026-08-17 |
| JAK Signaling in Depression and Cognition in Male Football Players Baricitinib - Depressive Symptoms, Cognitive Symptom | Phase 2 | Recruiting | Emory University | 30 | 2026-10-01 | 2026-09-24 |
| US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 32 | 2026-10-01 | 2026-10-07 |
| Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Not yet recruiting | University of Massachusetts, Worcester | 40 | 2026-10-01 | 2026-09-10 |
| Digital STEADI Efficacy Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2 - Fall, Mild Cognitive Impairment (MCI) | Phase 1 / Phase 2 | Recruiting | Friendi.fi Corporation | 300 | 2026-09-04 | 2026-10-01 |
| Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure Simvastatin, Baricitinib - ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure | Phase 2 | Not yet recruiting | University of Colorado, Denver | 300 | 2026-09-01 | 2026-10-08 |
| Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough BCS+inactive, BCS+active - Chronic Cough (CC), Refractory Chronic Cough | Phase 2 | Recruiting | University of Montana | 135 | 2026-08-13 | 2026-08-18 |
| A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer axelopran, Pembolizumab - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 1 / Phase 2 | Not yet recruiting | Glycyx Therapeutics | 18 | 2026-07-15 | 2026-07-15 |
| MDMA-Assisted Massed Exposure Therapy for PTSD 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE) - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Emory University | 200 | 2026-07-01 | 2026-05-26 |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| Psilocybin-Assisted Therapy psilocybin, Supportive Therapy, Prolonged Exposure Therapy - PTSD | Phase 2 | Recruiting | Emory University | 150 | 2026-06-08 | 2026-10-01 |
| SMART Diets for MASLD Essential Amino Acids Supplementation intervention, Low sugar diet - Metabolic-dysfunction Associated Steatotic Liver Disease | Phase 2 | Recruiting | Michigan State University | 102 | 2026-06-01 | 2026-06-01 |
| CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV PDS0101 - HPV Associated Cancers, HIV (Human Immunodeficiency Virus) | Phase 2 | Withdrawn | University of California, San Diego | 2026-04-30 | 2026-08-19 | |
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment Zanidatamab, Resection, Patient Observation - Colon Carcinoma, Colorectal Carcinoma | Phase 2 | Recruiting | Emory University | 38 | 2026-04-07 | 2026-04-17 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
Showing 20 of 305. Sign in to see all of them.
Breast Neoplasms (16) · Prostatic Neoplasms (13) · Multiple Myeloma (12) · Anemia, Sickle Cell (10) · Squamous Cell Carcinoma of Head and Neck (8) · Stress Disorders, Post-Traumatic (8) · Brain Neoplasms (7) · Glioblastoma (7) · Neoplasms (7) · Pancreatic Neoplasms (7) · Cognitive Dysfunction (6) · Depression (6) · Hypertension (6) · Inflammation (6) · Lung Neoplasms (6)
Magnetic Resonance Spectroscopy (18) · Specimen Handling (15) · pembrolizumab (15) · Cyclophosphamide (13) · Dexamethasone (11) · Gemcitabine (11) · Nivolumab (11) · Biopsy (10) · Calcium Dobesilate (9) · Cisplatin (8) · Radiotherapy (8) · Taxes (8) · Albumin-Bound Paclitaxel (7) · Bortezomib (7) · Docetaxel (7)
United States (279) · Canada (3) · Armenia (1) · Australia (1) · Bangladesh (1) · China (1) · Georgia (1) · Guatemala (1) · Hong Kong (1) · Ireland (1) · Puerto Rico (1) · South Africa (1) · United Kingdom (1) · Zambia (1)
Arshed A Quyyumi, MD (5) · Elisavet Paplomata, MD (4) · Nadine Rouphael, MD (4) · Olumide B. Gbolahan, MBBS, MSc (4) · Andrew H Miller, MD (3) · Arshed Quyyumi, MD (3) · Jeanie Park, MD (3) · Nabil F. Saba, MD (3) · Taofeek Owonikoko, MD, PhD (3) · Thomas R Ziegler, MD (3) · Ajay Nooka, MD, MPH (2) · Amelia Langston, MD (2) · Amelia Zelnak, MD (2) · Andrew Hendrick, MD (2) · Arlene Chapman, M.D. (2)
PMID 32384147, PMID 36240296, PMID 42549972, PMID 18278987, PMID 18550258, PMID 18779478, PMID 19258546, PMID 19528374, PMID 19861511, PMID 20056649, PMID 20332274, PMID 20516268, PMID 20883542, PMID 21084270, PMID 21346146, PMID 21456040, PMID 21555712, PMID 21724580, PMID 21832112, PMID 21926600, PMID 22149065, PMID 22264573, PMID 22353006, PMID 22449224, PMID 22488002, PMID 22535574, PMID 22549432, PMID 22924607, PMID 22964475, PMID 23170065, PMID 23332349, PMID 23471421, PMID 23517449, PMID 23718572, PMID 23881549, PMID 24085777, PMID 24145657, PMID 24166893, PMID 24247554, PMID 24675657, PMID 24743802, PMID 24925526, PMID 24950747, PMID 25103371, PMID 25184864, PMID 25272149, PMID 25365551, PMID 25393772, PMID 25648989, PMID 25760881
P30CA138292 (58), K24AT009893 (2), R01HL135183 (2), R21AT004509 (2), U01CA113913 (2), U19AI090023 (2), U54CK000601 (2), 1RC2HL101515-01 (1), 1RF1AG051514 (1), F30CA206291 (1), K08CA279766 (1), K23CA164015 (1), K23DK099442 (1), K23HL098744 (1), K23HL166775 (1)